US FDA rejects defence of gene-therapy trial.

Reports on the rejection by the United States Food and Drug Administration (FDA) of arguments made by the University of Pennsylvania in defense of its gene-therapy program. Shutdown of the trial by the FDA after the death of Jesse Gelsinger and the discovery of several protocol violations; Basis of the university's response to allegations over questionable safety standards; Demands of the FDA before the program could be reinstituted.